GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (NAS:PHXM) » Definitions » Interest Expense (Positive)

PHAXIAM Therapeutics (PHAXIAM Therapeutics) Interest Expense (Positive)


View and export this data going back to 2015. Start your Free Trial

What is PHAXIAM Therapeutics Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.


PHAXIAM Therapeutics (PHAXIAM Therapeutics) Business Description

Traded in Other Exchanges
Address
60 Avenue Rockefeller, Lyon, FRA, 69008
Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.